1-1 of 1
Jason Kato, PhD
Close
Sort by
Journal Articles

The HB22.7 Anti-CD22 Monoclonal Antibody Is an Effective Platform for CD22-Targeted Antibody Drug Conjugates for Treatment of Lymphoma and Acute Lymphoblastic Leukemia

Soames F. Boyle, MD, Jason Kato, PhD, Robert O'Donnell, MD, PhD, Joseph Tuscano, MD
Journal: Blood
Blood (2012) 120 (21): 1653.
https://doi.org/10.1182/blood.V120.21.1653.1653
Published: 2012